Unlock instant, AI-driven research and patent intelligence for your innovation.

A pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, its preparation method and use

An application and mutant technology, applied in the field of pyrrolo[2,3-d]pyrimidine derivatives and their preparation, can solve the problems of osimertinib drug resistance and other problems, and achieve good application prospects, significant inhibitory effect, good Inhibitory activity and selective effects

Active Publication Date: 2022-04-19
WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, however, a study showed that resistance to osimertinib has emerged

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, its preparation method and use
  • A pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, its preparation method and use
  • A pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Embodiment 1, the synthesis of key intermediate 1

[0079] The synthetic route of key intermediate 1 is as follows:

[0080]

[0081] in,

[0082] When X=Br, intermediate 1 is compound 10, and key intermediate 1 is compound 14;

[0083] When X=I, intermediate 1 is compound 11, and key intermediate 1 is compound 15;

[0084] When X=OH, intermediate 1 is compound 12, and key intermediate 1 is compound 16;

[0085] X=OCH 3 , the intermediate 1 is compound 13, and the key intermediate 1 is compound 17.

[0086] Alternatively, the synthetic route of the key intermediate 1 is as follows:

[0087]

[0088] X=NO 2 , the key intermediate 1 is compound 18.

[0089] The specific preparation method is as follows:

[0090] (1) Synthesis of 1-(2-iodo-4-nitrobenzene)-4-methylpiperazine (11): 4-fluoro-3-iodonitrobenzene (1.34g, 5.0mmol), N- The mixed solution of methylpiperazine (about 6ml, 52mmol) was heated to 90°C, reacted for more than 5h, left at room temperature, d...

Embodiment 2

[0099] Embodiment 2, the synthesis of key intermediate 2

[0100] The synthetic route of key intermediate 2 is as follows:

[0101]

[0102] The specific preparation method is as follows:

[0103] Synthesis of compound 19: Add 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (4.68g, 0.025mol) into a round bottom flask, dissolve in THF, and then add chloromethyl pivalate (7.5g, 0.05mol) and potassium carbonate (0.1mol, 13.8g), stirred at room temperature for 5 minutes, then raised the temperature to 80°C to reflux. Continue to react for about 12h, TLC monitoring shows that the reaction is complete (developing agent: CH 2 Cl 2 ). After the reaction solution is cooled, spin the reaction solution to dryness, add 150ml of water and CH 2 Cl 2 (300ml×3) for extraction, combined the organic phases, added an appropriate amount of anhydrous sodium sulfate to dry, filtered, and concentrated. The crude product was separated by silica gel column chromatography (eluent: CH 2 Cl 2 ) to o...

Embodiment 3

[0105] Embodiment 3, the synthesis of compound 1 of the present invention

[0106] The synthetic route of compound 1 is as follows:

[0107]

[0108] The specific preparation method is as follows:

[0109] Synthesis of compound 21: add t-BuOH (50ml), key intermediate 2 (compound 20) (1.21g, 3mmol), 3-fluoro-4-(4-methylpiperazine)-aniline ( 522 mg, 2.5 mmol). The above reaction solution was stirred at room temperature for 5-10 min. Potassium carbonate (690mg, 5mmol), Pd 2 (dba) 3 (230mg, 0.25mmol, a catalyst that catalyzes the formation of carbon-nitrogen bonds), XPhos (ie 2-dicyclohexylphosphorus-2,4,6-triisopropylbiphenyl, 120mg, 0.25mmol), the reaction was mixed The solution was refluxed and stirred for about 6 hours at 110°C, and the reaction was monitored by TLC (developing agent: CH 2 Cl 2 / CH 3 OH=10 / 1, v / v). The reaction solution was cooled to room temperature, spin-dried, extracted, dried, concentrated, and separated by silica gel column chromatography (elu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, its preparation method and application, and belongs to the field of chemical medicine. The derivative is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The compound of the present invention has low toxicity to normal cells, and has obvious inhibitory effect on lung cancer cell lines, especially has good selectivity for EGFR mutant cell HCC827 cells, and the inhibitory effect is remarkable; at the same time, the compound of the present invention can effectively inhibit the phosphorylation of EGFR . In addition, the compound of the present invention has good inhibitory activity and selectivity to mutant EGFR. The compound of the present invention can be used to treat lung cancer, especially non-small cell lung cancer, which has a strong inhibitory effect on EGFR mutant lung cancer and has low toxicity; the present invention can also be used to prepare tyrosine kinase inhibitors, especially EGFR Phosphorylation inhibitors have good application prospects.

Description

technical field [0001] The invention belongs to the field of chemical medicine, and specifically relates to a pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, a preparation method and application thereof. Background technique [0002] Lung cancer is the malignant tumor with the highest morbidity and mortality worldwide, and the number of deaths due to lung cancer reaches 1.6 million each year. It is the main cause of cancer-related deaths in men (22% of cancer deaths) and women (13.8% of cancer deaths) reason. In the United States, about 14 percent of new cancers are lung cancers. The American Cancer Society estimates there were approximately 234,000 lung cancer cases and 154,000 deaths in the United States in 2018. The situation in my country is equally serious. According to the latest cancer data in China released by the National Cancer Center in January 2019, lung cancer is the malignant tumor with the highest morbidity and mortality in my country. Come unde...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D487/04A61P35/00A61P35/02A61K31/519
CPCC07D487/04A61P35/00A61P35/02
Inventor 李为民夏贞强黄日东何杨周兴龙陈海罗雨蕉吴琼
Owner WEST CHINA HOSPITAL SICHUAN UNIV